BSRBR-RAUK CRN ID: 7302

July 2014 update

Recruitment Certolizumab

Must have diagnosis of

RA

Must be registered within 6 months of first dose of certolizumab

Can be re-registered if already on the

study

TocilizumabMust have

diagnosis of RA

Must be registered within 6 months of first

dose of IV or S/C tocilizumab

Can be re-registered if already on the

study

Anti-TNF Comparison CohortMust have

diagnosis of RA

Must be registered within 6 months of first dose of etanercept, adalimumab or infliximab

Numbers recruited up to 30/06/2014

854As of 30/06/2014

956As of 30/06/2014

720As of 30/06/2014

Recruitment over the last year

Certolizumab recruitment by month (1 July 2013 – 30 June 2014)

Tocilizumab recruitment by month (1 July 2013 – 30 June 2014)

Anti-TNF cohort recruitment by month (1 July 2013 – 30 June 2014)

Jul-13

Aug-13

Sep-13

Oct-13

Nov-13

Dec-13

Jan-14

Feb-14

Mar-14

Apr-14

May-14

Jun-1405

10152025303540

3531

12 13Number recruitedTrendline

Jul-13

Aug-13

Sep-13

Oct-13

Nov-13

Dec-13

Jan-14

Feb-14

Mar-14

Apr-14

May-14

Jun-140

102030405060

4250

26

39

25 Number recruitedTrendline

Jul-13

Aug-13

Sep-13

Oct-13

Nov-13

Dec-13

Jan-14

Feb-14

Mar-14

Apr-14

May-14

Jun-1405

1015202530

2328

12

26

Number recruitedTrendline

Recruitment 01/01/2014 – 30/06/2014

BSR Region Awards January 2014 – July 2014

North West East

of England

West Midlands

69 56 50

East Midlands

Recent BSRBR-RA publications– Risk of solid cancer in patients exposed to anti-TNF therapy: results from the

BSRBR-RA. Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. &Hyrich, K (2014). Ann Rheum Dis, [Epub ahead of print]

- Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.

McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, Hyrich KL. (2013) Rheumatology (Oxford), [Epub ahead of print]

– The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & (2013). Ann Rheum Dis, [Epub ahead of print]

Accessing BSRBR-RA data• You can access data from the BSRBR-RA via a “third party data request form” (contact ARoach@rheumatology.org.uk for a copy).

• Proposals should be discussed with Kath.watson@manchester.ac.ukKimme.hyrich@manchester.ac.ukin advance of submission to discuss feasibility.

•Proposals can be submitted at any time of the year – there are no submission deadlines.

http://www.rheumatology.org.uk/resources/bsr_biologics_registers/

Recent/ongoing research projects via the BSRBR-RA data access scheme

Non-inflammatory pain mechanisms as confounders in the clinical assessment of synovitis in RA

Study of fatigue in inflammatory arthritis

Effectiveness of TNF response define by season of initiation of therapy, with particular focus on vitamin D

To explore the influence of gender and gender-related variables on severity of prognosis for RA

Obesity and clinical response to anti-TNF medication

Contacts

Email: biologics.register@manchester.ac.uk

Tel: 0161 275 1652/7390

Web: http://man.ac.uk/mS3HTm

Twitter: @BSRBR_RA

Acknowledgements

• UK Consultant Rheumatologists and Specialist Nurses

• UK Comprehensive Research Networks

• BSRBR-RA Control Centre Consortium

• British Society for Rheumatology

• Arthritis Research UK Centre for Epidemiology, Manchester